Charles Schwab Investment Management Inc. Buys 44,970 Shares of Enovis Co. (NYSE:ENOV)

Charles Schwab Investment Management Inc. boosted its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 7.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 645,789 shares of the company's stock after acquiring an additional 44,970 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.14% of Enovis worth $28,337,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ENOV. Amalgamated Bank increased its stake in Enovis by 1.0% in the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company's stock valued at $1,136,000 after buying an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after acquiring an additional 300 shares during the period. UMB Bank n.a. boosted its position in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the last quarter. New York State Teachers Retirement System grew its stake in Enovis by 3.5% in the 4th quarter. New York State Teachers Retirement System now owns 13,538 shares of the company's stock valued at $594,000 after purchasing an additional 457 shares during the period. Finally, FMR LLC increased its position in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Remove Ads

Enovis Price Performance

Shares of NYSE:ENOV traded down $0.23 on Friday, hitting $39.12. The company's stock had a trading volume of 407,368 shares, compared to its average volume of 669,771. The company has a market capitalization of $2.23 billion, a PE ratio of -17.86 and a beta of 2.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The company has a 50-day simple moving average of $42.84 and a 200 day simple moving average of $43.56. Enovis Co. has a 1 year low of $35.14 and a 1 year high of $62.79.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.06. The business had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Sell-side analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC decreased their price target on shares of Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 27th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.